Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action

A class action lawsuit has been filed against ADMA Biologics, Inc. for alleged securities fraud. Culper Research published a report accusing the company of channel stuffing, undisclosed related party transactions, and inflating revenue growth. The stock fell 29.1% over two trading days following the allegations. Shareholders who purchased ADMA securities between August 9, 2024 and March 25, 2026 can file claims by August 10, 2026.